recent
studi
establish
feasibl
subunitbas
experiment
vaccin
protect
anim
lethal
poxviru
infect
individu
outer
membran
protein
intracellular
extracellular
virion
vaccinia
viru
deliv
form
either
dna
vaccin
recombin
protein
vaccin
produc
baculovirusinfect
insect
cell
abl
protect
mice
vaccinia
viru
challeng
rhesu
macaqu
monkeypox
viru
challeng
polyval
formul
variou
combin
four
poxviru
antigen
achiev
better
protect
monoval
formul
use
one
antigen
howev
clear
whether
remain
outer
membran
poxviru
protein
improv
efficaci
current
polyval
formul
studi
conduct
detail
analysi
immunogen
previous
report
protect
antigen
intracellular
matur
virion
result
indic
induc
strong
protect
antibodi
respons
effect
improv
efficaci
previous
report
polyval
poxviru
vaccin
formul
therefor
excel
candid
antigen
includ
final
polyval
subunitbas
poxviru
vaccin
success
vaccin
campaign
led
global
erad
smallpox
result
estim
half
world
popul
naiv
smallpox
infect
rais
public
concern
potenti
bioterror
use
smallpox
type
poxviru
biolog
weapon
henderson
time
origin
smallpox
vaccin
longer
produc
due
safeti
concern
tradit
manufactur
process
newer
gener
vaccin
made
attenu
vaccinia
virus
grown
tissu
cultur
cell
shown
promis
immunogen
initi
studi
artenstein
et
al
earl
et
al
weltzin
et
al
wyatt
et
al
howev
studi
still
need
establish
scaleup
product
vaccin
confirm
safeti
profil
larger
human
popul
although
vaccinia
viru
potent
vaccin
distinct
abil
produc
long
last
immun
human
crotti
et
al
demkowicz
et
al
natur
protect
antigen
begun
reveal
fogg
et
al
hooper
et
al
pulford
et
al
correspond
epitop
involv
activ
host
immun
respons
b
cell
level
lead
protect
immun
much
less
understood
recent
studi
demonstr
excit
feasibl
develop
subunitbas
smallpox
vaccin
dna
recombin
protein
vaccin
use
individu
outer
membran
protein
vaccinia
viru
elicit
protect
antibodi
respons
small
anim
nonhuman
primat
model
fogg
et
al
hooper
et
al
dna
vaccin
formul
includ
two
intracellular
matur
virion
imv
antigen
encod
gene
two
extracellular
envelop
virion
eev
antigen
vaccinia
viru
abl
protect
mice
virolog
wwwelseviercomlocateyviro
intraperiton
vaccinia
viru
challeng
hooper
et
al
subsequ
protect
rhesu
macaqu
monkeypox
viru
challeng
hooper
et
al
similarli
abl
formul
recombin
poxviru
protein
produc
baculoviru
system
also
abl
protect
mice
lethal
intranas
vaccinia
challeng
fogg
et
al
howev
studi
also
indic
current
subunitbas
formul
still
less
effect
live
attenu
smallpox
vaccin
dryvax
first
polyval
formul
need
protect
none
individu
outer
membran
protein
use
monoval
vaccin
abl
elicit
protect
mous
model
poxviru
challeng
effect
vaccinia
vaccin
second
multipl
immun
requir
achiev
protect
efficaci
protect
mice
receiv
recombin
protein
abl
formul
becam
close
posit
control
use
poxviru
vaccin
vvwyeth
vaccin
fogg
et
al
similarli
immun
need
dna
vaccin
formul
nonhuman
primat
reduc
diseas
sever
mild
moder
level
onetim
dryvax
immun
could
achiev
complet
control
diseas
progress
hooper
et
al
therefor
necessari
improv
current
subunitbas
poxviru
vaccin
commit
larg
scale
human
test
exact
mechan
live
attenu
vaccinia
vaccin
could
gener
better
protect
subunitbas
vaccin
clear
possibl
live
attenu
vaccin
induc
better
cell
respons
may
either
provid
helper
function
enhanc
magnitud
qualiti
protect
antibodi
respons
add
cytotox
cell
compon
mechan
protect
also
highli
like
addit
antigen
includ
recent
report
subunitbas
poxviru
vaccin
studi
may
abl
improv
protect
complic
pathogen
smallpox
expand
breadth
protect
includ
improv
polyval
formul
therefor
logic
identifi
addit
poxviru
antigen
may
provid
better
immun
protect
among
nearli
protein
vaccinia
viru
least
six
report
elicit
neutral
antibodi
pulford
et
al
rodriguez
smith
ramirez
et
al
frank
et
al
ichihashi
oie
wolff
et
al
hsiao
et
al
law
smith
engelstad
et
al
engelstad
smith
lin
et
al
chertov
et
al
davi
et
al
wallengren
et
al
antibodi
abl
inhibit
comet
format
galmich
et
al
antigen
studi
variou
subunitbas
polyval
poxviru
vaccin
formul
fogg
et
al
hooper
et
al
includ
studi
gene
vaccinia
viru
encod
imv
envelop
protein
involv
cellsurfac
bind
adsorpt
imv
cell
maa
et
al
antibodi
detect
mice
immun
vaccinia
viru
demkowicz
et
al
replic
vaccinia
brain
tissu
significantli
reduc
gene
inactiv
recombin
virus
cherno
et
al
recombin
protein
produc
e
coli
express
system
modifi
gene
sequenc
induc
neutral
antibodi
abl
block
vaccinia
infect
cell
hsiao
et
al
dna
immun
construct
induc
partial
protect
vaccinia
challeng
mous
studi
although
overal
immunogen
poxviru
dna
vaccin
studi
appear
low
poxvirusspecif
antibodi
detect
dnavaccin
mice
pulford
et
al
neutral
antibodi
activ
report
dna
vaccin
importantli
clear
whether
abl
improv
protect
previous
report
poxviru
antigen
includ
part
polyval
formul
report
immun
mice
form
optim
dna
vaccin
design
abl
induc
vaccinia
neutral
antibodi
respons
provid
protect
lethal
vaccinia
challeng
effect
improv
protect
efficaci
polyval
poxviru
vaccin
formul
vaccinia
gene
code
protein
clone
dna
vaccin
vector
use
cmv
ie
promot
drive
express
code
antigen
insert
order
produc
immunogen
form
dna
vaccin
two
version
gene
insert
produc
fig
first
one
full
length
code
sequenc
wild
type
gene
version
transmembran
tm
region
downstream
cytoplasm
tail
remov
human
tissu
plasminogen
activ
tpa
leader
sequenc
ad
n
terminu
code
gene
wild
type
gene
encod
natur
leader
sequenc
previou
dna
vaccin
studi
tpa
leader
abl
increas
secret
env
sarscov
protein
immunogen
wang
et
al
similar
approach
ad
leader
sequenc
remov
tm
region
report
effect
achiev
good
express
recombin
protein
hsiao
et
al
express
dna
vaccin
examin
western
blot
use
cultur
supernat
cell
lysat
cell
transient
transfect
two
dna
vaccin
plasmid
clear
dna
vaccin
higher
level
express
construct
fig
particularli
effect
increas
secret
antigen
supernat
appar
molecular
weight
protein
higher
supernat
suggest
involv
posttransl
process
step
modifi
gene
design
one
possibl
glycosyl
protein
sinc
three
put
nglycan
site
treatment
transient
express
protein
pngasef
inde
reduc
molecular
weight
lysat
supernat
precursor
form
fig
support
newli
express
cell
glycosyal
interestingli
express
vaccinia
viru
mainli
nonglycosyl
form
base
appar
molecular
weight
resist
pngasef
treatment
fig
ident
newli
express
antigen
confirm
strong
reactiv
mous
sera
immun
vaccinia
viru
protein
express
cell
fig
immunogen
form
dna
vaccin
test
balbc
mice
anim
receiv
four
biweekli
gene
gunmedi
dna
immun
serum
igg
respons
went
immun
measur
elisa
data
shown
reach
peak
level
week
fourth
dna
immun
fig
dna
vaccin
elicit
posit
igg
respons
geometr
mean
titer
dna
vaccin
group
higher
dna
vaccin
group
either
recombin
antigen
produc
cell
fig
lysat
vero
cell
infect
vaccinia
viru
fig
expect
posit
control
mous
sera
immun
vaccinia
viru
wr
strain
higher
titer
cell
lysat
infect
vaccinia
viru
recombin
antigen
due
presenc
multipl
poxviru
antigen
infect
cell
lysat
likewis
level
antibodi
elicit
dna
vaccin
higher
elicit
vaccinia
viru
wr
strain
presum
due
fact
antibodi
part
broad
antibodi
respons
wide
rang
antigen
sera
immun
vaccinia
virus
mous
sera
elicit
dna
vaccin
abl
neutral
vaccinia
viru
measur
plaqu
reduct
assay
fig
dna
vaccin
induc
higher
neutral
antibodi
dna
vaccin
somewhat
unexpect
neutral
titer
sera
almost
mous
sera
immun
vaccinia
viru
fig
appear
either
high
titer
antibodi
one
major
poxviru
antigen
rel
lower
titer
immun
sera
multipl
poxviru
antigen
could
achiev
neutral
effect
measur
vitro
neutral
assay
imv
form
poxviru
protect
potenti
antigen
either
alon
combin
report
protect
poxviru
antigen
evalu
balbc
mice
lethal
vaccinia
challeng
seri
challeng
studi
mous
receiv
four
biweekli
gene
gunmedi
dna
vaccin
fix
total
dose
dna
plasmid
vaccin
protect
studi
first
conduct
lethal
dose
vaccinia
viru
pfu
per
anim
deliv
intraperiton
ip
rout
result
high
dose
viru
challeng
control
mice
inocul
empti
dna
vector
lose
weight
progress
death
earli
day
challeng
fig
tabl
form
dna
vaccin
deliv
alon
abl
protect
mice
continu
weight
loss
ultim
death
compar
control
group
mice
receiv
empti
dna
vector
fig
none
dna
vaccin
mice
die
dna
vaccin
appear
slightli
effect
control
weight
loss
dna
vaccin
neither
effect
posit
control
immun
vaccinia
viru
wr
strain
fig
consist
previou
report
singl
poxviru
antigen
vaccin
could
achiev
level
protect
provid
live
attenu
poxviru
vaccin
fogg
et
al
hooper
et
al
pulford
et
al
data
first
report
antigen
alon
abl
achiev
protect
lethal
vaccinia
challeng
next
evalu
whether
dna
vaccin
includ
previous
report
subunitbas
polyval
poxviru
vaccin
fogg
et
al
hooper
et
al
improv
efficaci
formul
dna
vaccin
construct
insert
use
studi
measur
antibodi
respons
weight
loss
indic
dna
vaccin
effect
dna
vaccin
dna
vaccin
express
individu
poxviru
antigen
produc
similar
previou
report
hooper
et
al
hooper
et
al
except
gene
insert
subclon
vector
also
use
dna
vaccin
describ
report
use
ip
rout
challeng
model
previous
report
efficaci
bival
formul
two
well
studi
protect
poxviru
antigen
significantli
improv
addit
dna
vaccin
third
compon
fig
mice
immun
bival
formul
lost
weight
day
challeng
wherea
mice
immun
formul
includ
lost
p
protect
provid
formul
similar
provid
vaccinia
viru
vaccin
addit
antigen
also
improv
protect
efficaci
previous
report
formul
minim
weight
loss
first
day
challeng
fig
studi
ip
challeng
model
mice
immun
formul
includ
antigen
regain
initi
bodi
weight
day
challeng
compar
day
formul
group
includ
p
find
confirm
airway
infect
model
mice
challeng
pfu
vaccinia
viru
deliv
intranas
rout
previous
report
galmich
et
al
studi
mice
receiv
formul
includ
stop
loos
weight
earlier
receiv
formul
fig
also
achiev
protect
mice
compar
protect
formul
lethal
challeng
fig
differ
surviv
two
formul
statist
signific
p
differ
bodi
weight
loss
order
understand
specif
antibodi
respons
individu
pox
antigen
includ
polyval
vaccin
formul
vaccinia
vaccin
detail
analys
conduct
mice
sera
immun
differ
polyval
vaccin
formul
includ
anim
studi
highli
immunogen
antigen
antibodi
highest
titer
especi
mice
receiv
bival
formul
fig
antibodi
titer
remain
high
mice
immun
either
formul
fig
similarli
antibodi
titer
high
mice
immun
either
formul
fig
less
immunogen
lower
antibodi
titer
autolog
antigen
fig
least
immunogen
among
antigen
includ
formul
fig
note
sinc
elisa
assay
carri
crude
lysat
cell
transient
transfect
dna
vaccin
low
titer
antibodi
may
attribut
either
low
level
specif
igg
low
level
express
cell
howev
induct
antivaccinia
antibodi
dna
immun
inde
confirm
western
blot
vaccinia
viru
data
shown
studi
total
dna
vaccin
dose
fix
matter
mani
antigen
compon
includ
variou
polyval
formul
less
drop
titer
ad
bival
formul
contain
otherwis
level
antigenspecif
antibodi
respons
show
small
drop
poxviru
antigen
ad
suggest
effect
antigen
dilut
due
addit
new
antigen
present
signific
mous
sera
immun
vaccinia
vaccin
posit
antibodi
poxviru
antigen
confirm
protein
effect
antigen
vaccinia
immun
howev
level
antibodi
vari
igg
titer
highest
igg
titer
lowest
vector
control
sera
sera
lack
particular
antigen
show
specif
reactiv
antigen
sera
mice
immun
polyval
dna
vaccin
high
titer
igg
respons
vaccinia
viru
vacv
antigen
titer
increas
antigen
ad
polyval
dna
vaccin
formul
fig
hand
antivacv
titer
vaccinia
viru
immun
mous
sera
lower
polyval
formul
find
suggest
vaccinia
viru
could
induc
antibodi
respons
broad
array
poxviru
antigen
subunitbas
polyval
formul
could
develop
higher
total
antibodi
respons
even
less
number
antigen
importantli
titer
antivacv
antibodi
respons
correl
protect
fig
level
neutral
antibodi
respons
also
analyz
assay
neutral
antibodi
mainli
target
imv
form
poxviru
previous
describ
hooper
et
al
polyval
formul
includ
report
elicit
posit
neutral
antibodi
respons
level
similar
even
better
induc
vaccinia
vaccin
fig
formul
includ
elicit
strongest
neutral
antibodi
respons
presum
due
combin
two
strong
imv
antigen
formul
less
effect
gener
neutral
antibodi
like
due
dilut
effect
number
antigen
compon
increas
progress
last
sever
year
establish
feasibl
subunitbas
smallpox
vaccin
deliv
form
dna
plasmid
hooper
et
al
hooper
et
al
recombin
protein
fogg
et
al
singl
imvor
eev
antigen
abl
provid
variou
level
protect
combin
antigen
form
polyval
formul
afford
better
protect
mice
vaccinia
viru
challeng
nonhuman
primat
monkeypox
challeng
fogg
et
al
hooper
et
al
hooper
et
al
hooper
et
al
polyval
vaccin
approach
attract
broader
immun
respons
gener
simultan
target
sever
antigen
principl
polyval
vaccin
prove
effect
licens
human
vaccin
polio
influenza
viru
pneumococcu
hurwitz
et
al
poxvirus
complex
pathogen
potenti
protect
antigen
target
well
studi
far
even
antigen
known
abl
induc
neutral
antibodi
includ
previous
report
polyval
formul
also
interest
observ
report
polyval
formul
abl
elicit
better
protect
live
attenu
poxviru
vaccin
mice
less
effect
protect
nonhuman
primat
hooper
et
al
hooper
et
al
therefor
effort
develop
subunitbas
poxviru
vaccin
futur
need
improv
polyval
vaccin
includ
identif
addit
protect
antigen
enhanc
broaden
protect
efficaci
current
studi
produc
dna
vaccin
express
protein
known
target
neutral
antibodi
includ
previous
report
polyval
poxviru
vaccin
protein
bind
glycosaminoglycan
cell
surfac
mediat
adsorpt
intracellular
matur
virion
cell
antibodi
rais
recombin
protein
neutral
imv
solubl
protein
inhibit
viral
absorpt
cell
competit
manner
modifi
poxvirus
inactiv
demonstr
dramat
reduc
infect
hsiao
et
al
immun
recombin
protein
induc
vacciniaspecif
antibodi
prolifer
respons
demkowicz
et
al
immun
dna
vaccin
induc
partial
protect
intranas
challeng
ihd
strain
pulford
et
al
howev
report
show
dna
vaccin
abl
induc
neutral
antibodi
clear
whether
antigen
improv
protect
efficaci
report
polyval
poxviru
formul
report
demonstr
dna
vaccineinduc
antigenspecif
neutral
antibodi
level
neutral
antibodi
similar
induc
vaccinia
vaccin
sera
recogn
vaccinia
infect
cell
lysat
mous
sera
induc
vaccinia
vaccin
signific
level
antibodi
previou
version
dna
vaccin
immunogen
immun
mice
posit
antibodi
respons
pulford
et
al
current
studi
use
optim
dna
vaccin
vector
includ
intron
sequenc
downstream
cmv
ie
promot
abl
enhanc
antigen
express
immunogen
dna
vaccin
wang
et
al
previou
dna
vaccin
use
entir
gene
insert
data
suggest
modifi
antigen
immunogen
addit
tpa
leader
remov
ctermin
region
includ
tm
cytoplasm
tail
facilit
secret
similar
gene
design
recombin
protein
express
report
hsiao
et
al
remov
ctermin
region
ad
tag
nterminu
bacteri
express
antigen
direct
comparison
wild
type
modifi
antigen
studi
util
dna
vaccin
tool
made
easier
us
demonstr
modifi
effect
wild
type
antigen
express
antibodi
respons
protect
lethal
poxviru
challeng
optim
dna
vaccin
construct
alon
abl
provid
surviv
immun
mice
lethal
poxviru
challeng
intraperiton
rout
even
though
mice
experienc
weight
loss
receiv
vaccinia
vaccin
addit
antigen
previous
report
formul
improv
protect
efficaci
measur
weight
loss
surviv
ip
challeng
model
anim
experienc
rapid
weight
loss
result
receiv
larg
amount
challeng
viru
contrast
challeng
model
use
fogg
et
al
proteinbas
poxviru
vaccin
mimic
upper
respiratori
rout
transmiss
smallpox
requir
lower
amount
viru
ip
challeng
take
day
develop
critic
weight
loss
studi
also
show
mice
suscept
vaccinia
challeng
ip
challeng
lethal
dose
viru
significantli
reduc
rout
challeng
mice
demonstr
high
morbid
mortal
later
time
post
challeng
suggest
differ
dynam
host
pathogen
interact
ip
challeng
experi
challeng
repres
stringent
test
sinc
polyval
formul
could
provid
surviv
ip
challeng
use
ip
challeng
model
current
studi
consist
result
report
hooper
et
al
also
use
dna
vaccin
deliv
subunit
poxviru
antigen
use
challeng
model
demonstr
signific
differ
polyval
formul
without
antigen
polyval
poxviru
vaccin
formul
deliv
dna
immun
effect
induc
protect
regardless
model
use
compar
neg
control
given
mani
differ
mice
human
result
highli
suggest
protect
potenti
polyval
poxviru
vaccin
true
efficaci
requir
protect
studi
nonhuman
primat
well
organ
human
clinic
trial
specifi
immunogen
biomark
may
correl
protect
studi
also
compar
antibodi
respons
individu
recombin
poxviru
antigen
antibodi
respons
entir
vaccinia
viru
neutral
antibodi
respons
elicit
differ
dna
vaccin
formul
vaccinia
vaccin
clear
level
antibodi
respons
partial
relat
amount
dna
plasmid
use
vaccin
increas
valenc
polyval
formul
fix
total
dose
regimen
effect
dose
individu
compon
reduc
level
antibodi
respons
individu
antigen
lower
howev
level
antibodi
respons
vaccinia
viru
increas
antigen
includ
polyval
formul
reflect
addit
effect
antibodi
respons
multipl
antigen
similar
vaccinia
vaccin
induc
broad
antibodi
respons
recogn
mani
poxviru
antigen
titer
antibodi
individu
poxviru
antigen
may
lower
induc
individu
subunitbas
vaccin
case
neutral
antibodi
respons
result
demonstr
mixtur
phenomena
anim
receiv
vaccin
formul
antigen
addit
anoth
strong
imv
antigen
increas
level
neutral
antibodi
respons
measur
imv
mediat
antibodi
respons
nonimv
antigen
ad
level
neutral
antibodi
respons
actual
reduc
interestingli
protect
correl
level
imvmedi
neutral
antibodi
respons
rather
better
protect
achiev
antigen
includ
vaccin
formul
way
mimick
vaccinia
vaccin
least
two
protect
mechan
account
first
polyval
poxviru
vaccin
formul
vaccinia
vaccin
also
includ
eev
antigen
thu
eevmedi
neutral
antibodi
may
play
import
role
part
protect
report
previou
studi
appleyard
et
al
boulter
appleyard
fogg
et
al
galmich
et
al
hooper
et
al
hooper
et
al
law
smith
second
cellmedi
immun
cmi
may
also
critic
protect
smallpox
infect
demkowicz
et
al
enni
et
al
frey
et
al
kennedi
et
al
find
increas
imv
neutral
antibodi
correl
increas
protect
import
impact
design
subunitbas
poxviru
vaccin
summari
demonstr
report
excel
candid
subunitbas
poxviru
vaccin
abl
induc
neutral
antibodi
protect
ip
challeng
model
mice
addit
antigen
interfer
high
immunogen
antigen
compon
previous
report
polyval
poxviru
vaccin
formul
result
prove
dna
immun
cost
effect
approach
screen
identifi
addit
protect
poxviru
antigen
ultim
format
subunitbas
poxviru
vaccin
deliv
form
dna
protein
combin
dna
prime
plu
protein
boost
benefit
deliveri
system
importantli
result
present
report
support
search
optim
group
protect
poxviru
antigen
polyval
poxviru
vaccin
final
best
protect
efficaci
sinc
poxvirus
complex
virus
may
reason
studi
protect
efficaci
addit
antigen
includ
less
well
studi
protect
mechan
final
select
candid
antigen
includ
subunitbas
polyval
poxviru
vaccin
formul
wr
strain
vaccinia
viru
vacv
provid
dr
liisa
selin
univers
massachusett
medic
school
propag
vero
cell
clarifi
cell
lysat
use
western
blot
analysi
elisa
vacv
stock
challeng
prepar
cell
selin
et
al
purifi
serum
contamin
centrifug
sucros
gradient
chen
et
al
viral
titer
assay
perform
vero
cell
selin
et
al
selin
et
al
individu
poxviru
gene
pcr
amplifi
wr
strain
vacv
use
pfu
dna
polymeras
stratagen
ca
dna
insert
subclon
cmv
immedi
earli
ie
promot
construct
pcr
amplifi
gene
subclon
vector
downstream
tpa
leader
sequenc
lu
et
al
wang
et
al
wang
et
al
dna
vaccin
plasmid
transform
e
coli
strain
confirm
restrict
digest
dna
sequenc
larg
amount
dna
plasmid
prepar
mega
purif
kit
qiagen
valencia
ca
report
poxviru
protein
refer
gene
relat
dna
vaccin
use
six
eight
week
old
femal
balbc
mice
purchas
tacon
farm
germantown
ny
hous
depart
anim
medicin
univers
massachusett
medic
school
umm
accord
iacuc
approv
protocol
anim
immun
helio
gene
gun
biorad
laboratori
hercul
ca
shave
abdomin
skin
previous
report
wang
et
al
mous
receiv
biweekli
immun
six
dna
shot
per
immun
least
mice
includ
group
immunogen
studi
mice
includ
protect
studi
blood
sampl
collect
periorbit
prior
first
immun
week
immun
mice
immun
vacv
receiv
pfu
vacv
pb
intraderm
inocul
ear
pinna
month
challeng
tschark
et
al
tschark
smith
pilot
rabbit
immun
studi
conduct
produc
rabbit
sera
use
western
blot
analysi
antigen
express
new
zealand
white
nzw
rabbit
kg
bodi
weight
purchas
millbrook
farm
amherst
rabbit
receiv
biweekli
immun
dna
vaccin
immun
gene
gun
shave
abdomin
skin
sera
collect
week
last
immun
rabbit
serum
use
western
blot
analysi
report
vaccinia
viru
antigen
use
antibodi
bind
assay
prepar
previous
describ
fogg
et
al
follow
modif
two
flask
confluent
vero
cell
infect
wr
strain
vacv
multipl
infect
moi
day
infect
cell
harvest
collect
centrifug
g
min
cell
pellet
resuspend
mm
trishcl
ph
freezethaw
time
follow
dounc
homogen
homogen
centrifug
min
supernat
aliquot
store
cell
transient
transfect
calcium
phosphat
coprecipit
method
use
plasmid
dna
cell
dish
cell
harvest
h
later
supernat
cell
lysat
collect
elisa
western
blot
use
supernat
multipl
dish
pool
amount
determin
coomassi
blue
stain
sdspolyacryamid
gel
electrophoresi
sdspage
gel
vaccinia
viru
antigenspecif
igg
respons
immun
mice
measur
elisa
use
individu
mous
sera
anim
group
elisa
plate
coat
antigen
harvest
cell
transient
transfect
dna
vaccin
plasmid
incub
overnight
antivacv
assay
elisa
plate
coat
pfu
vacv
per
well
fix
paraformaldehyd
serial
dilut
mous
ad
well
assay
duplic
block
plate
incub
biotinyl
antimous
igg
vector
laboratori
burlingam
ca
dilut
per
well
follow
horseradish
peroxidaseconjug
streptavidin
vector
laboratori
dilut
final
develop
sigmaaldrich
st
loui
mo
solut
per
well
reaction
stop
ad
h
plate
read
nm
endpoint
titer
calcul
serum
dilut
result
absorb
greater
standard
deviat
absorb
well
incub
neg
control
mous
serum
cell
transient
transfect
calcium
phosphat
coprecipit
method
use
plasmid
dna
cell
dish
harvest
h
later
amount
transient
express
antigen
ng
protein
load
sdspage
transfer
onto
pvdf
membran
biorad
hercul
ca
block
overnight
block
buffer
iqblock
pb
membran
incub
dilut
rabbit
sera
immun
correspond
dna
vaccin
wash
blot
incub
alkalin
phosphataseconjug
goat
antirabbit
igg
tropix
bedford
dilut
h
room
temperatur
signal
detect
use
chemiluminesc
westernlight
kit
tropix
bedford
glycosyl
studi
peptid
nglycosidas
f
pngasef
new
england
biolab
beverli
ad
denatur
sampl
prepar
supernat
transient
transfect
cell
accord
manufactur
instruct
incub
overnight
sampl
load
onto
sdspage
analyz
western
blot
describ
fifti
percent
plaqu
reduct
titer
determin
standard
techniqu
frey
et
al
briefli
sera
immun
anim
heat
inactiv
min
serial
dilut
antibodi
incub
pfu
vacv
h
confluent
vero
cell
monolay
infect
antibodyviru
mixtur
h
wash
pb
incub
liquid
overlay
day
monolay
stain
crystal
violet
min
plaqu
count
neutral
calcul
percentag
number
plaqu
count
reduc
test
serum
assay
compar
mean
plaqu
count
three
viru
control
without
sera
assay
age
match
femal
balbc
mice
per
group
use
experi
two
week
last
immun
balbc
mice
anesthet
intramuscularli
ketaminexylasin
inject
pfu
wr
strain
vacv
pb
intraperiton
rout
altern
bablc
mice
week
last
immun
receiv
pfu
wr
strain
vacv
pb
intranas
inocul
mice
weigh
observ
daili
previous
describ
selin
et
al
experi
done
complianc
protocol
approv
iacuc
ibc
univers
massachusett
medic
school
test
perform
use
epi
softwar
window
avail
form
cdc
web
site
surviv
curv
analyz
use
kaplanmei
test
comparison
mean
percentag
bodyweight
chang
differ
group
day
challeng
perform
use
unpair
twotail
student
test
microsoft
excel
softwar
version
consult
biostatistician
signific
level
set
p
valu
less
